Virginia 2024 Regular Session Status: Enacted

HB 1333 — Drug Control Act; adds certain chemicals to Schedules I, II, IV, and V of Act.

Last action — Acts of Assembly Chapter text (CHAP0062)

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. ✓
    Passed House of Delegates
  4. ✓
    Passed Senate
  5. ✓
    To Executive
  6. 6
    Enacted

This bill has been enacted into law. Introduced January 11, 2024. Enacted.

Signed by Governor Glenn Youngkin (Republican) on March 08, 2024.

Odds of enactment

High chance

Based on the sponsor, cosponsors, and committee posture, this bill has a high chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Likely to advance 70% · moderate confidence
  • Enacted

    Current position in the legislative process.

  • 1 sponsor

    1 primary, 0 co-sponsors signed on.

  • Cleared a recorded vote

    Passed 5 recorded votes so far.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

Summary

Drug Control Act; Schedule I; Schedule II; Schedule IV; Schedule V. Adds certain chemicals to Schedules I, II, IV, and V of the Drug Control Act. The Board of Pharmacy has added these substances in an expedited regulatory process. A substance added via this process is removed from the schedule after 18 months unless a general law is enacted adding the substance to the schedule. This bill incorporates HB 1450 and is identical to SB 111.

Bill Text

What changed in the latest version

871 added · 839 removed

Plain-language change summary

The recent amendment to HB 1333 updates specific sections of Virginia's Drug Control Act by modifying the language related to controlled substances classified under Schedule I. The main change involves clarifying the terms and removing some repetitive phrasing, which streamlines the definitions of certain opiates and related compounds. This matters because clearer language helps law enforcement and healthcare professionals better understand the legal status of these substances, potentially improving public safety and regulatory enforcement.

→
Previous
Latest
SESSION ENROLLED VIRGINIA ACTS OF ASSEMBLY –– CHAPTER E An Act to amend and reenact §§ 54.1-3446, 54.1-3448, 54.1-3452, and 54.1-3454 of the Code of N Virginia, relating to Drug Control Act;
VIRGINIA ACTS OF ASSEMBLY -- 2024 SESSION CHAPTER 62 An Act to amend and reenact §§ 54.1-3446, 54.1-3448, 54.1-3452, and 54.1-3454 of the Code of Virginia, relating to Drug Control Act;
R O [H 1333] Approved L L Be it enacted by the General Assembly of Virginia:
[H 1333] Approved March 8, 2024 Be it enacted by the General Assembly of Virginia:
That §§ 54.1-3446, 54.1-3448, 54.1-3452, and 54.1-3454 of the Code of Virginia are amended aEd reenacted as follows:
That §§ 54.1-3446, 54.1-3448, 54.1-3452, and 54.1-3454 of the Code of Virginia are amended and reenacted as follows:
D The controlled substances listed in this section are included in Schedule I:
§ 54.1-3446.
Schedule I.
The controlled substances listed in this section are included in Schedule I:
Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:
Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and1-{1-[1-(4-bromophenyl)ethyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one (other name:
1-{1-[1-(4-bromophenyl)ethyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one (other name:
2-methyl AP-23H);
2-methyl AP-237);
1 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol (other name:
1-(4-cinnamyl-2,6-dimethylpiperazin-1-yl)propan-1-one (other name:
AP-238);
1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol (other name:
E 2-(4-ethoxybenzyl)-5-nitro-1-[2-(pyrrolidin-1-yl)ethyl]-1H-benzimidazole (other names:
2-(4-ethoxybenzyl)-5-nitro-1-[2-(pyrrolidin-1-yl)ethyl]-1H-benzimidazole (other names:
2-methoxy-N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-aceta(other name:
2-methoxy-N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide (other name:
3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzamide (other name:
U-47700);
AH-7921););
AH-7921);
Benzethidine;
Difenoxin;
Etoxeridine;
of 15 Ketobemidone;
Ketobemidone;
Levophenacylmorphan;
of 14 Levophenacylmorphan;
N-[1-[2-(4-methylphenyl)ethyl]piperidin-4-yl]-N-phenylacet(other name:
N-[1-[2-(4-methylphenyl)ethyl]piperidin-4-yl]-N-phenylacetamide (other name:
N,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-(other name:
N,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine (other name:
of 15 Metodesnitazene);
Metodesnitazene);
E Protonitazene);
Protonitazene);
R N-phenyl-N-(4-piperidinyl)-propanamide (other name:
of 14 N-phenyl-N-(4-piperidinyl)-propanamide (other name:
Noracymethadol;
O Normethadone;
Normethadone;
L Norpipanone;
Norpipanone;
E N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide (other name:
N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide (other name:
D N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide (other name:
N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide (other name:
thiophene fenPhenadoxone;
thiophene fentanyl);
Phenadoxone;
H Piritramide;
Piritramide;
B Proheptazine;
Proheptazine;
3 Properidine;
Properidine;
R Racemoramide;
Racemoramide;
Trimeperidine;
2-methyl-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide (name:
2-methyl-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide (other name:
Show all 197 changed rows (157 more)
Previous
Latest
2-(2,4-dichlorophenyl)-N-[2-(dimethylamino)cyclohexyl]-N-methyl acetamide (other name:
U-48800);
N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)pentana(other names:
N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)pentanamide (other names:
N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]acet(other name:
N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (other name:
4-mN-phenyl-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide (other name:
4-methoxybutyrylfentanyl);
N-phenyl-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide (other name:
N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-cyclopentanecarbox(other name:
N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-cyclopentanecarboxamide (other name:
Phenyl fentanyl, Benzoyl fenN-[2-(dimethylamino)cyclohexyl]-N-phenylfuran-2-carboxamide (other name:
Phenyl fentanyl, Benzoyl fentanyl);
N-[2-(dimethylamino)cyclohexyl]-N-phenylfuran-2-carboxamide (other name:
of 15 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-isopropyl-benzamide (other name:
3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-isopropyl-benzamide (other name:
Acetyldihydrocodeine;
of 14 Acetyldihydrocodeine;
of 15 Salvinorin A;
Salvinorin A;
E 2,5-DMA);
2,5-DMA);
R 3,4-methylenedioxy-N-ethylamphetamine (also known as N-ethyl-alpha-methyl-3,4 (meN-hydroxy-3,4-methylenedioxyamphetamineA, MDE, MDEA);
3,4-methylenedioxy-N-ethylamphetamine (also known as N-ethyl-alpha-methyl-3,4 (methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA);
(some other names:
N-hydroxy-3,4-methylenedioxyamphetamine (some other names:
O N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA);
N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA);
L 4-bromo-2,5-dimethoxyamphetamine (some trade or other names:
4-bromo-2,5-dimethoxyamphetamine (some trade or other names:
L 4-methoxyamphetamine (some trade or other names:
of 14 4-methoxyamphetamine (some trade or other names:
E paramethoxyamphetamine;
paramethoxyamphetamine;
N-ethyl-1-phenylcyclohexylamine, D (1-phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE);
N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE);
1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHPThiophene analog of phencyclidine (some other names:
1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP);
Thiophene analog of phencyclidine (some other names:
H 4-methylmethcathinone (other names:
4-methylmethcathinone (other names:
B 3,4-methylenedioxymethcathinone (other name:
3,4-methylenedioxymethcathinone (other name:
3 Naphthylpyrovalerone (other name:
Naphthylpyrovalerone (other name:
R 4-methoxymethcathinone (other names:
4-methoxymethcathinone (other names:
3,4-methylenedioxyethcathinone (other name:
ethylone);
4-Iodo-2,5-dimethoxyphenethylamine (other name:
2C-I);
name:
2C-I);
25-I, 25IMethoxetamine (other names:
25-I, 25I-NBOMe, 2C-I-NBOMe);
Methoxetamine (other names:
(2-aminopropyl)benzofuran (other name:
APB);
of 15 2C-C-NBOMe, 25C-NBOMe, 25C);
2C-C-NBOMe, 25C-NBOMe, 25C);
Beta-keto-4-bromo-2,5-dimethoxyphenethylamine (other name:
of 14 Beta-keto-4-bromo-2,5-dimethoxyphenethylamine (other name:
1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)-1-pentan(other names:
1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)-1-pentanone (other names:
of 15 4-ethyl-2,5-dimethoxy-N-[(2-hydroxyphenyl)methyl]-benzeneethanamine (other name:
4-ethyl-2,5-dimethoxy-N-[(2-hydroxyphenyl)methyl]-benzeneethanamine (other name:
E 4-hydroxy-N-ethyl-N-propyltryptamine (other name:
4-hydroxy-N-ethyl-N-propyltryptamine (other name:
N-Isobutyl Hexedrone, N alpha-isobutylaminohexanphenone);
N-Isobutyl Hexedrone, alpha-isobutylaminohexanphenone);
R 1-(4-methoxyphenyl)-N-methylpropan-2-amine (other names:
1-(4-methoxyphenyl)-N-methylpropan-2-amine (other names:
para-Methoxymethamphetamine, PMMN-ethyl-1-(3-hydroxyphenyl)cyclohexylamine (other name:
para-Methoxymethamphetamine, PMMA);
N-ethyl-1-(3-hydroxyphenyl)cyclohexylamine (other name:
O N-heptyl-3,4-dimethoxyamphetamine (other name:
N-heptyl-3,4-dimethoxyamphetamine (other name:
L N-hexyl-3,4-dimethoxyamphetamine (other name:
N-hexyl-3,4-dimethoxyamphetamine (other name:
L 4-fluoro-alpha-methylamino-valerophenone (other name:
4-fluoro-alpha-methylamino-valerophenone (other name:
E N-(1,4-dimethylpentyl)-3,4-dimethoxyamphetamine (other name:
N-(1,4-dimethylpentyl)-3,4-dimethoxyamphetamine (other name:
D Alpha-pyrrolidinocyclohexanophenone (other name:
Alpha-pyrrolidinocyclohexanophenone (other name:
1-(1,3-benzodioxol-5-yl)-2-(cyclohexylamino)butan-1-one (other names:
4-chloro-alpha-methylaminobutiophenone (other name:
4-chloro Buphedrone);
of 14 1-(1,3-benzodioxol-5-yl)-2-(cyclohexylamino)butan-1-one (other names:
H 1-[1-(3-chlorophenyl)cyclohexyl]-piperidine (other names:
1-[1-(3-chlorophenyl)cyclohexyl]-piperidine (other names:
3-Chloro Phencyclidine, 3Cl-PCP, B 3-chloro PCP);
3-Chloro Phencyclidine, 3Cl-PCP, 3-chloro PCP);
3 1-[1-(3-fluorophenyl)cyclohexyl]piperidine (other names:
1-[1-(3-fluorophenyl)cyclohexyl]piperidine (other names:
R 5-methoxy-3,4-methylenedioxyamphetamine, 3-methoxy MDA, MMDA);
5-methoxy-3,4-methylenedioxyamphetamine, 3-methoxy MDA, MMDA);
N-ethylpentedrone, alp2-(ethylamino)-2-(2-fluorophenyl)-cyclohexanone (other names:
N-ethylpentedrone, alpha-ethylaminopentiophenone);
2-(ethylamino)-2-(2-fluorophenyl)-cyclohexanone (other names:
Alpha-pyrrolidino-2-phenylacetophenone (other name:
alpha-D2PV).
Etizolam;etizolam;
Deschloroetizolam;
Etizolam;
Bromonordiazepam);l-1,3-dihydro-1,4-benzodiazepin-2-one (other names:
7-bromo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one (other names:
Desalkylgidazepam, 7-chloro-5-(2-chlorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one (other names:
Desalkylgidazepam, Bromonordiazepam);
Diclazepam, of 15 2-Chlorodiazepam);
7-chloro-5-(2-chlorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one (other names:
8-bromo-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodia(other names:
Diclazepam, 2-Chlorodiazepam);
8-bromo-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine(other names:
N-methyl-1-(thiophen-2-yl)propan-2-amine (other name:
of 14 N-methyl-1-(thiophen-2-yl)propan-2-amine (other name:
N-(adamantyl)-indole-3-carboxamide with substitution at the nitrogen atom of the indole ring, of 15 whether or not further substituted on the indole ring to any extent, whether or not substituted on the adamantyl ring to any extent;
N-(adamantyl)-indole-3-carboxamide with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the adamantyl ring to any extent;
and E N-(adamantyl)-indazole-3-carboxamide with substitution at a nitrogen atom of the indazole ring, whether or not further substituted on the indazole ring to any extent, whether or not substituted on the adamantyl ring to any extent.
and N-(adamantyl)-indazole-3-carboxamide with substitution at a nitrogen atom of the indazole ring, whether or not further substituted on the indazole ring to any extent, whether or not substituted on the adamantyl ring to any extent.
R b.
b.
ADB-5Br-INACA);-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-indazole-3-carboxamide (other name:
5-bromo-N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-indazole-3-carboxamide (other name:
O 5-(1,1-Dimethylheptyl)-2-[3-hydroxycyclohexyl]-phenol (other name:
ADB-5Br-INACA);
5-(1,1-Dimethylheptyl)-2-[3-hydroxycyclohexyl]-phenol (other name:
L 5-(1,1-Dimethylhexyl)-2-[3-hydroxycyclohexyl]-phenol (other name:
5-(1,1-Dimethylhexyl)-2-[3-hydroxycyclohexyl]-phenol (other name:
L 5-(1,1-Dimethylnonyl)-2-[3-hydroxycyclohexyl]-phenol (other name:
5-(1,1-Dimethylnonyl)-2-[3-hydroxycyclohexyl]-phenol (other name:
E 1-pentyl-3-(1-naphthoyl)indole (other names:
1-pentyl-3-(1-naphthoyl)indole (other names:
D 1-pentyl-3-(2-methoxyphenylacetyl)indole (other name:
1-pentyl-3-(2-methoxyphenylacetyl)indole (other name:
1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (other name:
JWH-200);
H 1-pentyl-3-(2-chlorophenylacetyl)indole (other name:
1-pentyl-3-(2-chlorophenylacetyl)indole (other name:
B 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (other name:
1-pentyl-3-(4-ethyl-1-naphthoyl)indole (other name:
3 1-pentyl-3-(4-chloro-1-naphthoyl)indole (other name:
of 14 1-pentyl-3-(4-chloro-1-naphthoyl)indole (other name:
R 1-((N-methylpiperidin-2-yl)methyl)-3-(1-naphthoyl)indole (other name:
1-((N-methylpiperidin-2-yl)methyl)-3-(1-naphthoyl)indole (other name:
Pravadolinelpi(4-methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]meth(other name:
1-[(N-methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole (other name:
AM-2233);
Pravadoline (4-methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone (other name:
1-pentyl-3-(1-adamantoyl)indole (other name:
AB-001);
ADB-PINACA);o-3,3-dimethyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide (other name:
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide (other name:
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxa(other name:
ADB-PINACA);
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide (other name:
1-naphthalenyl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (other name:
NM-2201);
of 15 N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide (other name:
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide (other name:
Methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbuta(other names:
Methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (other names:
N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxam(other names:
N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (other names:
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)indazole-3-carbo(other name:
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)indazole-3-carboxamide (other name:
Methyl 2-[1-4-fluorobutyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (other name:
of 14 Methyl 2-[1-4-fluorobutyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (other name:
Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutan(other names:
Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate(other names:
of 15 Ethyl 2-[1-pentyl-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (other name:
Ethyl 2-[1-pentyl-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (other name:
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-phenethyl-1H-indazole-3-carboxam(other name:
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-phenethyl-1H-indazole-3-carboxamide (other name:
E ADB-PHETINACA);
ADB-PHETINACA);
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indole-3-ace(other names:
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indole-3-acetami(other names:
N ADB-FUBIATA, AD-18, FUB-ACADB).
ADB-FUBIATA, AD-18, FUB-ACADB).
R § 54.1-3448.
§ 54.1-3448.
The controlled substances listed in this section are included in Schedule II:
Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, naldemedine, nalmefene, nalExone, naltrexone and their respective salts, but including the following:
Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, naldemedine, nalmefene, naloxone, naltrexone and their respective salts, but including the following:
D Opium extracts;
Opium extracts;
Powdered opium;
H Ethylmorphine;
Ethylmorphine;
B Etorphine hydrochloride;
Etorphine hydrochloride;
3 Hydrocodone;
Hydrocodone;
R Metopon;
Metopon;
Oripavine (3-O-demethylthebaine or 6,7,8,14-tetradehydro-4, 5-aMorphine;y-6-methoxy-17-methylmorphinan-3-ol);
Oripavine (3-O-demethylthebaine or 6,7,8,14-tetradehydro-4, 5-alpha-epoxy-6-methoxy-17-methylmorphinan-3-ol);
Noroxymorphone;
Morphine;
of 14 Noroxymorphone;
compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions which do not contain cocaine or ecgonine;
Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions which do not contain cocaine or ecgonine;
Anileridine;;
Alphaprodine;
Anileridine;
Metazocine;;
Levorphanol;
Metazocine;
of 15 Methadone –– Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
Methadone –– Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
5.
of 14 5.
of 15 Chlordiazepoxide;
Chlordiazepoxide;
E Clonazepam;
Clonazepam;
N Clotiazepam;
Clotiazepam;
R Cloxazolam;
Cloxazolam;
Delorazepam;;
Daridorexant;
O Diazepam;
Delorazepam;
L Dichloralphenazone;
Diazepam;
Dichloralphenazone;
L Ethchlorvynol;
Ethchlorvynol;
E Ethinamate;
Ethinamate;
D Fludiazepam;
Fludiazepam;
Flurazepam;
H Lemborexant;
Lemborexant;
B Loprazolam;
Loprazolam;
3 Lorazepam;
Lorazepam;
R Mebutamate;
Mebutamate;
Meprobamate;;
Methohexital;
Meprobamate;
Oxazolam;
of 14 Oxazolam;
Petrichloral;
Zaleplon;;
Triazolam;
Zaleplon;
Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of specific chemical designation:tence of such salts, isomers, and salts of isomers is possible within the Cathine (+)-norpseudoephedrine;
Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
of 15 Diethylpropion;
Cathine (+)-norpseudoephedrine;
Diethylpropion;
Not more than 200 milligrams of codeine, or any of its salts, per 100 milliliters or per 100 grams;
of 14 Not more than 200 milligrams of codeine, or any of its salts, per 100 milliliters or per 100 grams;
of 15 Gabapentin [1-(aminomethyl)cyclohexaneacetic acid];
Gabapentin [1-(aminomethyl)cyclohexaneacetic acid];
E Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide];
Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide];
N Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid].carbonyl)pyridine-2-yl-benzamide];
Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide];
Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid].
That the provisions of this act may result in a net increase in periods of imprisonment or R necessary appropriation is $0 for periods of imprisonment in state adult correctional facilities and is $0 for periods of commitment to the custody of the Department of Juvenile Justice.
That the provisions of this act may result in a net increase in periods of imprisonment or commitment.
L L E D H 3 R
Pursuant to § 30-19.1:4 of the Code of Virginia, the estimated amount of the necessary appropriation is $0 for periods of imprisonment in state adult correctional facilities and is $0 for periods of commitment to the custody of the Department of Juvenile Justice.
View plain text versions (4)

Action History

  1. Acts of Assembly Chapter text (CHAP0062)

  2. Approved by Governor-Chapter 62 (effective 7/1/24)

  3. Governor's Action Deadline 11:59 p.m., March 8, 2024

  4. Enrolled Bill communicated to Governor on March 1, 2024

  5. Signed by President

  6. Signed by Speaker

  7. Impact statement from DPB (HB1333ER)

  8. Bill text as passed House and Senate (HB1333ER)

  9. Enrolled

  10. Passed Senate (39-Y 0-N)

  11. Read third time

  12. Constitutional reading dispensed (38-Y 0-N)

  13. Reported from Education and Health (13-Y 0-N)

  14. Referred to Committee on Education and Health

  15. Constitutional reading dispensed

  16. VOTE: Block Vote Passage (98-Y 0-N)

  17. Read third time and passed House BLOCK VOTE (98-Y 0-N)

  18. Engrossed by House - committee substitute HB1333H1

  19. Committee substitute agreed to 24106671D-H1

  20. Read second time

  21. Read first time

  22. Impact statement from DPB (HB1333H1)

  23. Incorporates HB1450 (Thomas)

  24. Committee substitute printed 24106671D-H1

  25. Reported from Health and Human Services with substitute (22-Y 0-N)

  26. Impact statement from DPB (HB1333)

  27. Impact statement from VCSC (HB1333)

  28. Referred to Committee on Health and Human Services

  29. Presented and ordered printed 24104366D

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 147 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (147)

147 members have not signed on to this bill.

Show all 147 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Votes

Passed Senate (39-Y 0-N)

Passed 39 Yea · 0 Nay · 1 Other
Party YeaNayPresentNot Voting
Unaffiliated 39001
Total 39001
% of votes cast 98%0%0%3%
How each member voted (40)

Official roll call →

Passed 38 Yea · 0 Nay · 2 Other
Party YeaNayPresentNot Voting
Unaffiliated 38002
Total 38002
% of votes cast 95%0%0%5%
How each member voted (40)

Official roll call →

Passed 13 Yea · 0 Nay · 2 Other
Party YeaNayPresentNot Voting
Unaffiliated 13002
Total 13002
% of votes cast 87%0%0%13%
How each member voted (15)

Official roll call →

Passed 97 Yea · 0 Nay · 2 Other
Party YeaNayPresentNot Voting
Unaffiliated 97002
Total 97002
% of votes cast 98%0%0%2%
How each member voted (99)
Member Party Vote
Adele Y. McClure — Yea
Alex Q. Askew — Yea
Alfonso H. Lopez — Yea
Amy J. Laufer — Yea
Anne Ferrell Tata — Yea
Arnold, Jonathan, E. P. — Yea
Atoosa R. Reaser — Yea
Batten, Amanda E. — Yea
Betsy B. Carr — Yea
Bill Wiley — Yea
Bonita G. Anthony — Yea
Briana D. Sewell — Yea
Bulova, David L. — Yea
C.E. Cliff Hayes, Jr. — Yea
Charniele L. Herring — Yea
Chris S. Runion — Yea
Convirs-Fowler, Kelly K. — Yea
Cordoza, A.C. — Yea
Coyner, Carrie E. — Yea
Dan I. Helmer — Yea
David A. Reid — Yea
Debra D. Gardner — Yea
Delores L. McQuinn — Yea
Delores Oates — Yea
Earley, Mark L., Jr. — Yea
Elizabeth B. Bennett-Parker — Yea
Ellen H. McLaughlin — Yea
Ennis, N. Baxter — Yea
Eric Phillips — Yea
Eric R. Zehr — Yea
Fowler, Hyland F."Buddy," Jr. — Yea
Freitas, Nicholas J. — Yea
Gilbert, C. Todd — Yea
Green, W. Chad — Yea
H. Otto Wachsmann, Jr. — Yea
Higgins, Geary — Yea
Holly M. Seibold — Yea
Irene Shin — Yea
Israel D. O'Quinn — Yea
Jackie H. Glass — Yea
James A. "Jay" Leftwich — Yea
James W. Morefield — Yea
Jason S. Ballard — Yea
Jeion A. Ward — Yea
Joseph P. McNamara — Yea
Joshua E. Thomas — Yea
Joshua G. Cole — Yea
Kannan Srinivasan — Yea
Karen Keys-Gamarra — Yea
Karrie K. Delaney — Yea
Kathy K.L. Tran — Yea
Katrina Callsen — Yea
Kent, Hillary Pugh — Yea
Knight, Barry D. — Yea
Laura Jane Cohen — Yea
LeVere Bolling, Destiny — Yea
Lovejoy, Ian T. — Yea
Luke E. Torian — Yea
M. Keith Hodges — Yea
Maldonado, Michelle Lopes — Not Voting
Marcia S. "Cia" Price — Yea
Marcus B. Simon — Yea
Marshall, Daniel W., III — Not Voting
Marty Martinez — Yea
Michael B. Feggans — Yea
Michael J. Jones — Yea
Michael J. Webert — Yea
Mike A. Cherry — Yea
Milde, Paul V. — Yea
Mundon King, Candi — Yea
Nadarius E. Clark — Yea
Obenshain, Chris — Yea
Orrock, Robert D., Sr. — Yea
Owen, David — Yea
Patrick A. Hope — Yea
Paul E. Krizek — Yea
Phil M. Hernandez — Yea
Phillip A. Scott — Yea
R. Lee Ware — Yea
Rae Cousins — Yea
Richard C. "Rip" Sullivan, Jr. — Yea
Robert S. Bloxom, Jr. — Yea
Rodney T. Willett — Yea
Rozia A. Henson, Jr. — Yea
Sam Rasoul — Yea
Scott A. Wyatt — Yea
Shelly A. Simonds — Yea
Sickles, Mark D. — Yea
Taylor, Kim A. — Yea
Terry G. Kilgore — Yea
Terry L. Austin — Yea
Thomas A. Garrett, Jr. — Yea
Thomas C. Wright, Jr. — Yea
Timothy P. Griffin — Yea
Tony O. Wilt — Yea
Vivian E. Watts — Yea
Wendell S. Walker — Yea
Will Davis — Yea
Wren M. Williams — Yea

Official roll call →

Passed 22 Yea · 0 Nay
Party YeaNayPresentNot Voting
Unaffiliated 22000
Total 22000
% of votes cast 100%0%0%0%
How each member voted (22)

Official roll call →

Subjects

Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HB 1333 do?
Drug Control Act; Schedule I; Schedule II; Schedule IV; Schedule V. Adds certain chemicals to Schedules I, II, IV, and V of the Drug Control Act. The Board of Pharmacy has added these substances in an expedited regulatory process. A substance added via this process is removed from the schedule after 18 months unless a general law is enacted adding the substance to the schedule. This bill incorporates HB 1450 and is identical to SB 111.
Who sponsors HB 1333?
HB 1333 is sponsored by H. Otto Wachsmann, Jr..
What is the current status of HB 1333?
This bill has been enacted into law. Introduced January 11, 2024. Enacted.
Where can I track HB 1333?
Track HB 1333 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB 1333

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Stay ahead of HB 1333

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →